Skip to main content
Erschienen in: Current Allergy and Asthma Reports 3/2011

01.06.2011

Guidelines 2.0: Do No Net Harm—The Future of Practice Guideline Development in Asthma and Other Diseases

verfasst von: Holger J. Schünemann

Erschienen in: Current Allergy and Asthma Reports | Ausgabe 3/2011

Einloggen, um Zugang zu erhalten

Abstract

Decisions are like double-edged swords: they always come with benefits and downsides. That is, any decision in life bears desirable and undesirable consequences, even if the latter only involves the time it takes to make or think about the decision, which can be considered the harm of decision making. Therefore, it is impossible to adhere to the Hippocratic Oath’s concept of “primum non nocere,” which is frequently interpreted as “never do harm.” The guiding principle for health care decision making should be to ensure that there is, in summary, more benefit than harm—in other words, “to do no net harm” (“primum non net nocere”). Practice guidelines support decision making and, as a consequence, would require the explicit consideration of both desirable and undesirable consequences, and assigning due considerations depending on the magnitude and importance of the consequences. The Grading of Recommendations Assessment, Development and Evaluation (GRADE) Working Group (http://​www.​gradeworkinggrou​p.​org) has made these considerations more explicit when developing health care recommendations. This article briefly summarizes the work of the GRADE working group based on examples of its application in the field of allergy and asthma, and provides an outlook for advances in the field of guideline development. These developments focus on funding of guidelines and handling conflict of interest, working with observational and diagnostic test accuracy studies, developing appropriate group processes, and the integration of values and preferences in the formulation of recommendations.
Literatur
1.
Zurück zum Zitat Terracciano L, Brozek J, Compalati E, Schunemann H. GRADE system: new paradigm. Curr Opin Allergy Clin Immunol. 2010;10(4):377–83.PubMedCrossRef Terracciano L, Brozek J, Compalati E, Schunemann H. GRADE system: new paradigm. Curr Opin Allergy Clin Immunol. 2010;10(4):377–83.PubMedCrossRef
2.
Zurück zum Zitat • Guyatt GH, Oxman AD, Schunemann HJ, Tugwell P, Knotterus A. GRADE guidelines: a new series of articles in the Journal of Clinical Epidemiology. J Clin Epidemiol. 2010 Dec 23. This is an introduction to a detailed series on GRADE and guideline development. It includes guidance from question development to group processes. • Guyatt GH, Oxman AD, Schunemann HJ, Tugwell P, Knotterus A. GRADE guidelines: a new series of articles in the Journal of Clinical Epidemiology. J Clin Epidemiol. 2010 Dec 23. This is an introduction to a detailed series on GRADE and guideline development. It includes guidance from question development to group processes.
3.
Zurück zum Zitat Schunemann HJ, Best D, Vist G, Oxman AD. Letters, numbers, symbols and words: how to communicate grades of evidence and recommendations. CMAJ. 2003;169(7):677–80.PubMed Schunemann HJ, Best D, Vist G, Oxman AD. Letters, numbers, symbols and words: how to communicate grades of evidence and recommendations. CMAJ. 2003;169(7):677–80.PubMed
4.
Zurück zum Zitat Atkins D, Best D, Briss PA, Eccles M, Falck-Ytter Y, Flottorp S, et al. Grading quality of evidence and strength of recommendations. BMJ. 2004;328(7454):1490.PubMedCrossRef Atkins D, Best D, Briss PA, Eccles M, Falck-Ytter Y, Flottorp S, et al. Grading quality of evidence and strength of recommendations. BMJ. 2004;328(7454):1490.PubMedCrossRef
5.
Zurück zum Zitat Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ. 2008;336(7650):924–6.PubMedCrossRef Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ. 2008;336(7650):924–6.PubMedCrossRef
6.
Zurück zum Zitat •• Brozek JL, Bousquet J, Baena-Cagnani CE, Bonini S, Canonica GW, Casale TB, et al. Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines: 2010 revision. J Allergy Clin Immunol. 2010;126(3):466–76. These are the new ARIA guidelines developed using the GRADE approach. •• Brozek JL, Bousquet J, Baena-Cagnani CE, Bonini S, Canonica GW, Casale TB, et al. Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines: 2010 revision. J Allergy Clin Immunol. 2010;126(3):466–76. These are the new ARIA guidelines developed using the GRADE approach.
7.
Zurück zum Zitat Schunemann HJ, Hill SR, Kakad M, Vist GE, Bellamy R, Stockman L, et al. Transparent development of the WHO rapid advice guidelines. PLoS Med. 2007;4(5):e119.PubMedCrossRef Schunemann HJ, Hill SR, Kakad M, Vist GE, Bellamy R, Stockman L, et al. Transparent development of the WHO rapid advice guidelines. PLoS Med. 2007;4(5):e119.PubMedCrossRef
8.
Zurück zum Zitat Barbui C, Dua T, van Ommeren M, Yasamy MT, Fleischmann A, Clark N, et al. Challenges in developing evidence-based recommendations using the GRADE approach: the case of mental, neurological, and substance use disorders. PLoS Med. 2010;7(8). Barbui C, Dua T, van Ommeren M, Yasamy MT, Fleischmann A, Clark N, et al. Challenges in developing evidence-based recommendations using the GRADE approach: the case of mental, neurological, and substance use disorders. PLoS Med. 2010;7(8).
9.
Zurück zum Zitat Fiocchi A, Schunemann HJ, Brozek J, Restani P, Beyer K, Troncone R, et al. Diagnosis and Rationale for Action Against Cow's Milk Allergy (DRACMA): a summary report. J Allergy Clin Immunol. 2010;126(6):1119–28 e12. Fiocchi A, Schunemann HJ, Brozek J, Restani P, Beyer K, Troncone R, et al. Diagnosis and Rationale for Action Against Cow's Milk Allergy (DRACMA): a summary report. J Allergy Clin Immunol. 2010;126(6):1119–28 e12.
10.
Zurück zum Zitat Fiocchi A, Brozek J, Schunemann H, Bahna SL, von Berg A, Beyer K, et al. World Allergy Organization (WAO) Diagnosis and Rationale for Action against Cow's Milk Allergy (DRACMA) guidelines. Pediatr Allergy Immunol. 2010;21 Suppl 21:1–125.PubMed Fiocchi A, Brozek J, Schunemann H, Bahna SL, von Berg A, Beyer K, et al. World Allergy Organization (WAO) Diagnosis and Rationale for Action against Cow's Milk Allergy (DRACMA) guidelines. Pediatr Allergy Immunol. 2010;21 Suppl 21:1–125.PubMed
11.
Zurück zum Zitat Schunemann HJ, Woodhead M, Anzueto A, Buist S, Macnee W, Rabe KF, et al. A vision statement on guideline development for respiratory disease: the example of COPD. Lancet. 2009;373(9665):774–9.PubMedCrossRef Schunemann HJ, Woodhead M, Anzueto A, Buist S, Macnee W, Rabe KF, et al. A vision statement on guideline development for respiratory disease: the example of COPD. Lancet. 2009;373(9665):774–9.PubMedCrossRef
12.
Zurück zum Zitat Eichacker PQ, Natanson C, Danner RL. Surviving sepsis–practice guidelines, marketing campaigns, and Eli Lilly. N Engl J Med. 2006;355(16):1640–2.PubMedCrossRef Eichacker PQ, Natanson C, Danner RL. Surviving sepsis–practice guidelines, marketing campaigns, and Eli Lilly. N Engl J Med. 2006;355(16):1640–2.PubMedCrossRef
13.
Zurück zum Zitat Rothman DJ, McDonald WJ, Berkowitz CD, Chimonas SC, DeAngelis CD, Hale RW, et al. Professional medical associations and their relationships with industry: a proposal for controlling conflict of interest. JAMA. 2009;301(13):1367–72.PubMedCrossRef Rothman DJ, McDonald WJ, Berkowitz CD, Chimonas SC, DeAngelis CD, Hale RW, et al. Professional medical associations and their relationships with industry: a proposal for controlling conflict of interest. JAMA. 2009;301(13):1367–72.PubMedCrossRef
14.
Zurück zum Zitat Lurie P, Almeida CM, Stine N, Stine AR, Wolfe SM. Financial conflict of interest disclosure and voting patterns at Food and Drug Administration Drug Advisory Committee meetings. JAMA. 2006;295(16):1921–8.PubMedCrossRef Lurie P, Almeida CM, Stine N, Stine AR, Wolfe SM. Financial conflict of interest disclosure and voting patterns at Food and Drug Administration Drug Advisory Committee meetings. JAMA. 2006;295(16):1921–8.PubMedCrossRef
15.
16.
Zurück zum Zitat Lo B, Fields M. Conflict of interest in medical research, education and practice. Washington: The National Academies Press, Institute of Medicine; 2009. Lo B, Fields M. Conflict of interest in medical research, education and practice. Washington: The National Academies Press, Institute of Medicine; 2009.
17.
Zurück zum Zitat Lo B, Fields M. Principles for identifying and assessing conflicts of interest. Conflict of interest in medical research, education and practice. Washington: National Academies Press, Institute of Medicine; 2009. Lo B, Fields M. Principles for identifying and assessing conflicts of interest. Conflict of interest in medical research, education and practice. Washington: National Academies Press, Institute of Medicine; 2009.
18.
Zurück zum Zitat Schunemann H, Osborne M, Moss J, Manthous C, Wagner G, Sicilian L, et al. An official American Thoracic Society Policy statement: managing conflict of interest in professional societies. Am J Respir Crit Care Med. 2009;180(6):564–80.PubMedCrossRef Schunemann H, Osborne M, Moss J, Manthous C, Wagner G, Sicilian L, et al. An official American Thoracic Society Policy statement: managing conflict of interest in professional societies. Am J Respir Crit Care Med. 2009;180(6):564–80.PubMedCrossRef
19.
Zurück zum Zitat Als-Nielsen B, Chen W, Gluud C, Kjaergard LL. Association of funding and conclusions in randomized drug trials: a reflection of treatment effect or adverse events? JAMA. 2003;290(7):921–8.PubMedCrossRef Als-Nielsen B, Chen W, Gluud C, Kjaergard LL. Association of funding and conclusions in randomized drug trials: a reflection of treatment effect or adverse events? JAMA. 2003;290(7):921–8.PubMedCrossRef
20.
Zurück zum Zitat Lexchin J, Bero LA, Djulbegovic B, Clark O. Pharmaceutical industry sponsorship and research outcome and quality: systematic review. BMJ. 2003;326(7400):1167–70.PubMedCrossRef Lexchin J, Bero LA, Djulbegovic B, Clark O. Pharmaceutical industry sponsorship and research outcome and quality: systematic review. BMJ. 2003;326(7400):1167–70.PubMedCrossRef
21.
Zurück zum Zitat Bradbury J. Storm over WHO-ISH hypertension guidelines. Lancet. 1999;353(9152):563.CrossRef Bradbury J. Storm over WHO-ISH hypertension guidelines. Lancet. 1999;353(9152):563.CrossRef
22.
Zurück zum Zitat Horton R. WHO: the casualties and compromises of renewal. The Lancet. 2002;359:1605–11.CrossRef Horton R. WHO: the casualties and compromises of renewal. The Lancet. 2002;359:1605–11.CrossRef
23.
Zurück zum Zitat Laing R, Waning B, Gray A, Ford N, Thoen E. 25 years of the WHO essential medicines lists: progress and challenges. Lancet. 2003;361(9370):1723–9.PubMedCrossRef Laing R, Waning B, Gray A, Ford N, Thoen E. 25 years of the WHO essential medicines lists: progress and challenges. Lancet. 2003;361(9370):1723–9.PubMedCrossRef
24.
Zurück zum Zitat McCarthy M. Critics slam draft WHO report on homeopathy. The Lancet. 2005;366(9487):705.CrossRef McCarthy M. Critics slam draft WHO report on homeopathy. The Lancet. 2005;366(9487):705.CrossRef
25.
Zurück zum Zitat Shaneyfelt TM, Mayo-Smith MF, Rothwangl J. Are guidelines following guidelines? The methodological quality of clinical practice guidelines in the peer-reviewed medical literature. JAMA. 1999;281(20):1900–5.PubMedCrossRef Shaneyfelt TM, Mayo-Smith MF, Rothwangl J. Are guidelines following guidelines? The methodological quality of clinical practice guidelines in the peer-reviewed medical literature. JAMA. 1999;281(20):1900–5.PubMedCrossRef
26.
Zurück zum Zitat Grilli R, Magrini N, Penna A, Mura G, Liberati A. Practice guidelines developed by specialty societies: the need for a critical appraisal. Lancet. 2000;355(9198):103–6.PubMedCrossRef Grilli R, Magrini N, Penna A, Mura G, Liberati A. Practice guidelines developed by specialty societies: the need for a critical appraisal. Lancet. 2000;355(9198):103–6.PubMedCrossRef
27.
Zurück zum Zitat Baverstock K. A time to ask what you want of WHO. Brit Med J. 2003;327(7406):111.CrossRef Baverstock K. A time to ask what you want of WHO. Brit Med J. 2003;327(7406):111.CrossRef
28.
Zurück zum Zitat Lantos PM, Charini WA, Medoff G, Moro MH, Mushatt DM, Parsonnet J, et al. Final report of the Lyme disease review panel of the infectious diseases society of America. Clin Infect Dis. 2010;51(1):1–5.PubMedCrossRef Lantos PM, Charini WA, Medoff G, Moro MH, Mushatt DM, Parsonnet J, et al. Final report of the Lyme disease review panel of the infectious diseases society of America. Clin Infect Dis. 2010;51(1):1–5.PubMedCrossRef
29.
Zurück zum Zitat Boyd EA, Baumann M, Curtis JR, Field M, Jaeschke R, Osborne M, et al., editors. Guideline Funding and Conflicts of Interest. The American Thoracic Society; 2011 (in press). Boyd EA, Baumann M, Curtis JR, Field M, Jaeschke R, Osborne M, et al., editors. Guideline Funding and Conflicts of Interest. The American Thoracic Society; 2011 (in press).
30.
Zurück zum Zitat Boyd EA, Bero LA. Assessing faculty financial relationships with industry: a case study. JAMA. 2000;284(17):2209–14.PubMedCrossRef Boyd EA, Bero LA. Assessing faculty financial relationships with industry: a case study. JAMA. 2000;284(17):2209–14.PubMedCrossRef
31.
Zurück zum Zitat Campbell EG. Doctors and drug companies–scrutinizing influential relationships. N Engl J Med. 2007;357(18):1796–7.PubMedCrossRef Campbell EG. Doctors and drug companies–scrutinizing influential relationships. N Engl J Med. 2007;357(18):1796–7.PubMedCrossRef
32.
Zurück zum Zitat Jacobs AK, Lindsay BD, Bellande BJ, Fonarow GC, Nishimura RA, Shah PM, et al. Task force 3: disclosure of relationships with commercial interests: policy for educational activities and publications. J Am Coll Cardiol. 2004;44(8):1736–40.PubMedCrossRef Jacobs AK, Lindsay BD, Bellande BJ, Fonarow GC, Nishimura RA, Shah PM, et al. Task force 3: disclosure of relationships with commercial interests: policy for educational activities and publications. J Am Coll Cardiol. 2004;44(8):1736–40.PubMedCrossRef
33.
Zurück zum Zitat Schunemann HJ, Hill SR, Kakad M, Bellamy R, Uyeki TM, Hayden FG, et al. WHO Rapid Advice Guidelines for pharmacological management of sporadic human infection with avian influenza A (H5N1) virus. Lancet Infect Dis. 2007;7(1):21–31.PubMedCrossRef Schunemann HJ, Hill SR, Kakad M, Bellamy R, Uyeki TM, Hayden FG, et al. WHO Rapid Advice Guidelines for pharmacological management of sporadic human infection with avian influenza A (H5N1) virus. Lancet Infect Dis. 2007;7(1):21–31.PubMedCrossRef
34.
Zurück zum Zitat Guyatt G, Akl EA, Hirsh J, Kearon C, Crowther M, Gutterman D, et al. The vexing problem of guidelines and conflict of interest: a potential solution. Ann Intern Med. 2010;152(11):738–41.PubMed Guyatt G, Akl EA, Hirsh J, Kearon C, Crowther M, Gutterman D, et al. The vexing problem of guidelines and conflict of interest: a potential solution. Ann Intern Med. 2010;152(11):738–41.PubMed
35.
Zurück zum Zitat Guyatt GH, Oxman AD, Kunz R, Vist GE, Falck-Ytter Y, Schunemann HJ. What is “quality of evidence” and why is it important to clinicians? BMJ. 2008;336(7651):995–8.PubMedCrossRef Guyatt GH, Oxman AD, Kunz R, Vist GE, Falck-Ytter Y, Schunemann HJ. What is “quality of evidence” and why is it important to clinicians? BMJ. 2008;336(7651):995–8.PubMedCrossRef
36.
Zurück zum Zitat Smith GC, Pell JP. Parachute use to prevent death and major trauma related to gravitational challenge: systematic review of randomised controlled trials. BMJ. 2003;327(7429):1459–61.PubMedCrossRef Smith GC, Pell JP. Parachute use to prevent death and major trauma related to gravitational challenge: systematic review of randomised controlled trials. BMJ. 2003;327(7429):1459–61.PubMedCrossRef
37.
Zurück zum Zitat Glasziou P, Chalmers I, Rawlins M, McCulloch P. When are randomised trials unnecessary? Picking signal from noise. BMJ. 2007;334(7589):349–51.PubMedCrossRef Glasziou P, Chalmers I, Rawlins M, McCulloch P. When are randomised trials unnecessary? Picking signal from noise. BMJ. 2007;334(7589):349–51.PubMedCrossRef
38.
Zurück zum Zitat Schunemann HJ, Oxman AD, Brozek J, Glasziou P, Bossuyt P, Chang S, et al. GRADE: assessing the quality of evidence for diagnostic recommendations. ACP J Club. 2008;149(6):2.PubMed Schunemann HJ, Oxman AD, Brozek J, Glasziou P, Bossuyt P, Chang S, et al. GRADE: assessing the quality of evidence for diagnostic recommendations. ACP J Club. 2008;149(6):2.PubMed
39.
Zurück zum Zitat Schunemann HJ, Fretheim A, Oxman AD. Improving the use of research evidence in guideline development: 10. Integrating values and consumer involvement. Health Res Policy Syst. 2006;4:22.PubMedCrossRef Schunemann HJ, Fretheim A, Oxman AD. Improving the use of research evidence in guideline development: 10. Integrating values and consumer involvement. Health Res Policy Syst. 2006;4:22.PubMedCrossRef
40.
Zurück zum Zitat Krahn M, Naglie G. The next step in guideline development: incorporating patient preferences. JAMA. 2008;300(4):436–8.PubMedCrossRef Krahn M, Naglie G. The next step in guideline development: incorporating patient preferences. JAMA. 2008;300(4):436–8.PubMedCrossRef
41.
Zurück zum Zitat Oxman AD, Bjorndal A, Becerra-Posada F, Gibson M, Block MA, Haines A, et al. A framework for mandatory impact evaluation to ensure well informed public policy decisions. Lancet. 2010;375(9712):427–31.PubMedCrossRef Oxman AD, Bjorndal A, Becerra-Posada F, Gibson M, Block MA, Haines A, et al. A framework for mandatory impact evaluation to ensure well informed public policy decisions. Lancet. 2010;375(9712):427–31.PubMedCrossRef
42.
Zurück zum Zitat Brouwers MC, Kho ME, Browman GP, Burgers JS, Cluzeau F, Feder G, et al. AGREE II: advancing guideline development, reporting and evaluation in health care. J Clin Epidemiol. 2010;63(12):1308–11.PubMedCrossRef Brouwers MC, Kho ME, Browman GP, Burgers JS, Cluzeau F, Feder G, et al. AGREE II: advancing guideline development, reporting and evaluation in health care. J Clin Epidemiol. 2010;63(12):1308–11.PubMedCrossRef
43.
Zurück zum Zitat Guyatt G, Oxman AD, Akl E, Kunz R, Vist G, Brozek J, et al. GRADE guidelines 1. Introduction-GRADE evidence profiles and summary of findings tables. J Clin Epidemiol/ 2010. Guyatt G, Oxman AD, Akl E, Kunz R, Vist G, Brozek J, et al. GRADE guidelines 1. Introduction-GRADE evidence profiles and summary of findings tables. J Clin Epidemiol/ 2010.
Metadaten
Titel
Guidelines 2.0: Do No Net Harm—The Future of Practice Guideline Development in Asthma and Other Diseases
verfasst von
Holger J. Schünemann
Publikationsdatum
01.06.2011
Verlag
Current Science Inc.
Erschienen in
Current Allergy and Asthma Reports / Ausgabe 3/2011
Print ISSN: 1529-7322
Elektronische ISSN: 1534-6315
DOI
https://doi.org/10.1007/s11882-011-0185-8

Weitere Artikel der Ausgabe 3/2011

Current Allergy and Asthma Reports 3/2011 Zur Ausgabe

Akuter Schwindel: Wann lohnt sich eine MRT?

28.04.2024 Schwindel Nachrichten

Akuter Schwindel stellt oft eine diagnostische Herausforderung dar. Wie nützlich dabei eine MRT ist, hat eine Studie aus Finnland untersucht. Immerhin einer von sechs Patienten wurde mit akutem ischämischem Schlaganfall diagnostiziert.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

HNO-Op. auch mit über 90?

16.04.2024 HNO-Chirurgie Nachrichten

Mit Blick auf das Risiko für Komplikationen nach elektiven Eingriffen im HNO-Bereich scheint das Alter der Patienten kein ausschlaggebender Faktor zu sein. Entscheidend ist offenbar, wie fit die Betroffenen tatsächlich sind.

Intrakapsuläre Tonsillektomie gewinnt an Boden

16.04.2024 Tonsillektomie Nachrichten

Gegenüber der vollständigen Entfernung der Gaumenmandeln hat die intrakapsuläre Tonsillektomie einige Vorteile, wie HNO-Fachleute aus den USA hervorheben. Sie haben die aktuelle Literatur zu dem Verfahren gesichtet.

Update HNO

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.